Accelerant's Q2 Ran Backwards: GAAP Beat Adjusted, and Two Reference Prices Explain the $20.25 Deal
Almost every quarter an American company reports, the non-GAAP number is the bigger one. Adjusted earnings exist because managements want to strip out charges they consider unrepresentative — restructuring, stock compensation, deal costs, amortization of acquired intangibles — and stripping out costs makes the remaining figure larger. Readers of earnings releases learn to expect the adjusted line to sit above the GAAP line, and to ask what was removed to get it there.
Accelerant Holdings ran that convention backwards on Thursday, Aug. 13, 2026. In its second-quarter release, distributed via Business Wire, the company reported GAAP net income of $80.0 million and GAAP diluted earnings per share of $0.36. Its adjusted, non-GAAP net income was $70.0 million, and adjusted diluted EPS was $0.32. The GAAP figure — unaudited, as interim results are — was $10.0 million higher than the management-preferred one — a difference this article computes from the two disclosed totals.
That inversion is the reporting story here, and it happened on the same morning Accelerant announced it had agreed to be acquired by Thoma Bravo and taken private at $20.25 per share in cash. The deal reframes everything in the release — the company cancelled its earnings call and withdrew its forward guidance because of it — but the quarter's mechanics are worth reading on their own terms, because they are unusually legible.
The release does break out the bridge, which is the first thing to check when GAAP exceeds adjusted. Starting from $80.0 million of GAAP net income, Accelerant subtracted $26.0 million of net realized gains on investments and $27.0 million of net unrealized gains on investments. It then added back $25.2 million of share-based compensation expenses and $26.8 million of other expenses, and subtracted a $9.0 million tax effect of adjustments, arriving at $70.0 million of adjusted net income.
Read that sequence and the reversal stops being strange. Accelerant removed $53.0 million of combined realized and unrealized investment gains and added back $52.0 million of share-based compensation and other expenses — both subtotals are this publication's addition of the release's own disclosed line items, not figures the company itself presents. The removals slightly exceeded the add-backs before tax, and the $9.0 million tax effect widened the gap the rest of the way. Nothing exotic happened. A large, non-recurring investment gain flowed through GAAP net income, and the company's own definition of adjusted earnings deliberately excludes it.
That exclusion is recent and disclosed. In its first-quarter 2026 release on May 13, 2026, Accelerant stated that "Beginning with first quarter of 2026, Accelerant updated definitions for these non-GAAP financial measures to exclude the impact of net realized and unrealized investment gains or losses." The company changed the rule one quarter before the quarter in which the rule produced a conspicuous result.
The first quarter shows why nobody noticed then. In Q1 2026, Accelerant's net realized gains on investments were $0.1 million and its net unrealized gains were $0.0 million, according to that same release. With essentially no investment gains to strip, the adjustment ran the ordinary way: a GAAP net loss of $4.1 million and GAAP diluted EPS of $(0.02) against adjusted net income of $37.7 million and adjusted diluted EPS of $0.17. The new definition was live; it simply had nothing to bite on.
Stack the two quarters and the point sharpens. For the six months ended June 30, 2026, Accelerant reported GAAP net income of $75.9 million against adjusted net income of $107.7 million — the conventional direction, adjusted comfortably above GAAP. The inversion is a second-quarter artifact of a single large mark on the investment portfolio, not a new relationship between the company's two earnings measures.
For an insurance business this is a familiar structural distinction rather than a controversy. Carriers and marketplaces hold sizable investment portfolios whose realized and unrealized marks swing with rates and credit spreads, and those swings are only loosely connected to whether the underwriting and fee businesses had a good three months. Excluding them cuts both ways: it removes the gains in a quarter like this one and would remove the losses in a quarter that went the other direction. The consequence a reader needs to hold onto is narrower — for Q2 2026, the adjusted figure is the more conservative of the two, and the GAAP figure is flattered by portfolio marks.
Underneath the reconciliation, the operating quarter was expansionary. Total revenue was $356.9 million against $219.1 million a year earlier, a 63% increase. Exchange written premium reached $1,322.3 million from $1,072.3 million, up 23%. Adjusted EBITDA — a non-GAAP measure — was $93.1 million against $63.6 million, at a 31% margin versus 29% in the prior-year quarter.
Chief Financial Officer Linda S. Huber said in the release: "Our second quarter financial results highlight the attractive growth and durability of our business. Exchange Written Premium grew 23% year-over-year and trailing twelve months premiums are now $4.6 billion. Our fee-based operating revenue and adjusted EBITDA, which we define as consolidated results less the underwriting segment, increased 56% and 91%, respectively, compared to the 2025 second quarter."
Against sell-side expectations, the adjusted line cleared comfortably. A Zacks write-up carried on TradingView reported that the $0.32 adjusted diluted EPS beat the Zacks Consensus Estimate of 16 cents. That comparison is a non-GAAP-to-non-GAAP one; the GAAP $0.36 is not the figure the consensus was set against.
Chairman and Chief Executive Jeff Radke is quoted twice in the release, in two separate passages. The first opens, "Accelerant has been building the preeminent specialty insurance marketplace since our founding in 2018." The second, which the release introduces with "Jeff Radke continued," begins, "We had a great second quarter financially, operationally, and strategically," and goes on, within that same quoted passage, to list the period's operational items — growth in third-party premium, a data agent the company calls ARC, the formation of a new third-party insurance company, and enhanced partnership agreements with three existing Accelerant Risk Exchange insurers. There was no call to press him on any of it: Accelerant said it would not host the conference call originally scheduled for Aug. 13, 2026, and would not provide third-quarter or full-year 2026 guidance, citing the pending acquisition. That is a routine consequence of signing a merger agreement, but it means the quarter’s most interesting disclosure — a non-GAAP definition change producing an inverted result one quarter later — went unquestioned by analysts on the record.
The deal itself: Thoma Bravo agreed to acquire Accelerant in an all-cash transaction at $20.25 per share, at an enterprise value of more than $4 billion, with closing expected in the first half of 2027, subject to shareholder approval and required regulatory approvals. Thoma Bravo's release describes the price as a 49% premium to Accelerant's closing share price on Aug. 12, 2026 — a Wednesday.
That premium claim checks out against a real quote. ARX closed at $13.61 on Wednesday, Aug. 12, 2026, according to historical price data at stockanalysis.com; $20.25 against that close is a premium of roughly 48.8%, this publication's arithmetic on the two figures, consistent with the company's rounded 49%. A $13.59 figure appears in some coverage; $13.59 is what back-solving $20.25 against the rounded 49% premium produces — this publication's arithmetic — and it is not the close on the tape.
The market repriced immediately. ARX closed at $19.51 on Thursday, Aug. 13, 2026, up 43.35% on volume of 70,080,006 shares traded, per stockanalysis.com. It then closed at $19.58 on Friday, Aug. 14, 2026, up 0.36%, on 19,772,773 shares traded, with the site stamping the data 4:00 PM EDT. Market capitalization was $4.25 billion against 217.19 million shares outstanding at that close.
Now the tension the release does not address. Accelerant's initial public offering priced at $21.00 per Class A common share on July 23, 2025, per the company's own pricing announcement; the shares began trading on the New York Stock Exchange under the ticker ARX on July 24, 2025, and the offering closed on July 25, 2025 after full exercise of the over-allotment option; 39,630,324 Class A common shares were sold in total, of which 20,276,280 were offered by Accelerant itself. The take-private price of $20.25 is $0.75 below that, a shortfall of roughly 3.6% — this publication's arithmetic on two separately sourced figures.
Both of the following are true, and the difference between them is entirely a question of which reference price is used. Measured against the Aug. 12, 2026 close of $13.61, $20.25 is a substantial premium. Measured against the $21.00 investors paid at the July 2025 IPO, $20.25 is a discount. Neither statement is wrong; they are answers to different questions. The premium describes what a holder gets relative to where the stock was trading the day before announcement. The IPO comparison describes what a buy-and-hold participant in the offering realizes across just under thirteen months. The company's 52-week range at the Friday close was $9.18 to $30.48, per stockanalysis.com, which is the range within which any choice of reference price sits.
Karen Meriwether, Chair of the Special Committee, said in the merger release: "The Special Committee believes this transaction recognizes the valuable platform and ecosystem that the Accelerant team has built, and provides immediate value to shareholders at a substantial premium." That statement is measured against the pre-announcement market price, not the offering price, and on that basis it is arithmetically supported. Radke, in the same release, said: "Returning to private ownership with Thoma Bravo's technology and software expertise, coupled with its vast financial and strategic resources, will enable us to make investments that further position our unique, data fueled platform to be the rails on which specialty insurance runs."
The shareholder-approval condition arrives with a large commitment already attached. Entities affiliated with Altamont Capital Partners holding shares representing approximately 82% of the company's outstanding voting rights have agreed to vote their shares in favor of the transaction. Altamont, described in the disclosure as Accelerant's largest investor, and the company's founders intend to retain equity ownership alongside Thoma Bravo, on terms the disclosure says will be finalized prior to closing. Note the noun: 82% of voting rights, which in a dual-class structure is not the same as 82% of shares outstanding, and the disclosure specifies voting rights.
Two structural terms matter for anyone tracking the timeline. If closing is delayed by certain pending insurance regulatory approvals, shareholders will receive a ticking fee accruing at 6% per annum for a period specified in the agreement — compensation for a long regulatory runway that runs into the first half of 2027. And the transaction carries no financing condition, because Thoma Bravo has provided an equity commitment to fund the purchase. Neither Thoma Bravo's release nor the 8-K summary reviewed for this article describes a go-shop provision; that is an absence in the documents reviewed rather than a confirmed prohibition, and the definitive merger agreement filed separately would govern.
On advisors, Morgan Stanley & Co. LLC is financial advisor to Accelerant, with Paul Hastings LLP as U.S. legal counsel, Sidley Austin LLP as insurance counsel and Maples Group as Cayman Islands counsel. Houlihan Lokey is financial advisor to the Special Committee, with Conyers Dill & Pearman as its legal counsel. Thoma Bravo is advised by Goodwin Procter LLP, with Skadden, Arps, Slate, Meagher & Flom LLP as insurance counsel and Walkers as Cayman Islands counsel, and BMO Capital Markets and Wells Fargo as financial advisors. Ropes & Gray LLP is advising Altamont.
What remains open is the gap between the last traded price and the contract price. ARX closed Friday, Aug. 14, 2026 at $19.58 against a $20.25 deal price — a spread of $0.67, or about 3.4% of the close, this publication's arithmetic. With no financing condition and a controlling holder committed to vote yes, that residual spread is a market observation about regulatory timing and the value of money over a runway extending into the first half of 2027, not a statement about the quarter Accelerant just reported.
And that quarter, stripped of the deal noise, says something small but precise: when a company changes what its adjusted number excludes, the change is invisible until the excluded item gets large. Accelerant's rewrite landed in the first quarter, when investment gains were $0.1 million and $0.0 million. It became visible in the second, when they were $26.0 million and $27.0 million, and the adjusted number fell below GAAP for the first time. The disclosure was there both times. Only the second one was hard to miss.
